147 related articles for article (PubMed ID: 25790771)
1. Association of MDM2 polymorphism with risk and prognosis of leukemia: a meta-analysis.
He X; Chen P; Yang K; Liu B; Zhang Y; Wang F; Guo Z; Liu X; Lou J; Chen H
Acta Haematol; 2015; 133(4):365-371. PubMed ID: 25790771
[TBL] [Abstract][Full Text] [Related]
2. Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.
Ding H; Dai Y; Ning Z; Fan N; Wang Z; Li P; Zhang L; Tao Y; Wang H
Medicine (Baltimore); 2016 Mar; 95(12):e2941. PubMed ID: 27015167
[TBL] [Abstract][Full Text] [Related]
3. MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.
Zhuo W; Zhang L; Ling J; Zhu B; Chen Z
Leuk Lymphoma; 2012 Nov; 53(11):2245-52. PubMed ID: 22563815
[TBL] [Abstract][Full Text] [Related]
4. Correlations between MDM2 gene SNP309 polymorphism and susceptibility to leukemia.
Ou WB
Med Sci Monit; 2015 Jan; 21():213-8. PubMed ID: 25600314
[TBL] [Abstract][Full Text] [Related]
5. Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis.
Yan YL; Han F; Tan WM; Wu CP; Qin X
Asian Pac J Cancer Prev; 2014; 15(16):6767-72. PubMed ID: 25169523
[TBL] [Abstract][Full Text] [Related]
6. Role of MDM2 T309G polymorphism in susceptibility and prognosis of nonsmall cell lung cancer: a meta-analysis.
Kong Q; Li P; Tian Q; Ha MW
Genet Test Mol Biomarkers; 2014 May; 18(5):357-65. PubMed ID: 24673452
[TBL] [Abstract][Full Text] [Related]
7. Correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility: An updated meta-analysis.
Yin L; Shen G; Zhu B
Thorac Cancer; 2020 Mar; 11(3):672-678. PubMed ID: 31970867
[TBL] [Abstract][Full Text] [Related]
8. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
9. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between Murine Double Minute 2 (MDM2) T309G Polymorphism and Endometrial Cancer Risk: A Meta-Analysis.
Xue Z; Zhu X; Teng Y
Med Sci Monit; 2016 Sep; 22():3186-90. PubMed ID: 27604213
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis.
Economopoulos KP; Sergentanis TN
Breast Cancer Res Treat; 2010 Feb; 120(1):211-6. PubMed ID: 19590949
[TBL] [Abstract][Full Text] [Related]
12. Association between murine double minute 2 T309G polymorphism and risk of liver cancer.
Tang T; Song X; Yang Z; Huang L; Wang W; Tan H
Tumour Biol; 2014 Nov; 35(11):11353-7. PubMed ID: 25119589
[TBL] [Abstract][Full Text] [Related]
13. Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls.
Zhuo W; Zhang L; Zhu B; Ling J; Chen Z
PLoS One; 2012; 7(7):e41546. PubMed ID: 22844496
[TBL] [Abstract][Full Text] [Related]
14. Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis.
Ma HB; Huang T; Han F; Chen WY
Asian Pac J Cancer Prev; 2012; 13(6):2841-6. PubMed ID: 22938470
[TBL] [Abstract][Full Text] [Related]
15. Contribution of Murine Double Minute 2 Genotypes to Colorectal Cancer Risk in Taiwan.
Yueh TC; Hung YW; Shih TC; Wu CN; Wang SC; Lai YL; Hsu SW; Wu MH; Fu CK; Wang YC; Ke TW; Chang WS; Tsai CW; Bau DT
Cancer Genomics Proteomics; 2018; 15(5):405-411. PubMed ID: 30194081
[TBL] [Abstract][Full Text] [Related]
16. The Relationship Between MDM2 T309G Polymorphism and Leukemia in the Chinese Population: Evidence from a Meta-Analysis.
Zhao D; Liu T
Clin Lab; 2017 Oct; 63(10):1639-1645. PubMed ID: 29035454
[TBL] [Abstract][Full Text] [Related]
17. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the MDM2 gene and risk of malignant bone tumors: a meta-analysis.
Tang J; Shen L; Song S; An Z; Zhang C
Tumour Biol; 2014 Jan; 35(1):779-84. PubMed ID: 23979978
[TBL] [Abstract][Full Text] [Related]
19. Is MDM2 SNP309 Variation a Risk Factor for Head and Neck Carcinoma?: An Updated Meta-Analysis Based on 11,552 Individuals.
Zhuo X; Ye H; Li Q; Xiang Z; Zhang X
Medicine (Baltimore); 2016 Mar; 95(9):e2948. PubMed ID: 26945408
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]